| First Author | Escobar G | Year | 2023 |
| Journal | Cancer Cell | Volume | 41 |
| Issue | 9 | Pages | 1662-1679.e7 |
| PubMed ID | 37625402 | Mgi Jnum | J:357689 |
| Mgi Id | MGI:7528538 | Doi | 10.1016/j.ccell.2023.08.001 |
| Citation | Escobar G, et al. (2023) Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell 41(9):1662-1679.e7 |
| abstractText | Stem-like CD8(+) T cells are regulated by T cell factor 1 (TCF1) and are considered requisite for immune checkpoint blockade (ICB) response. However, recent findings indicate that reliance on TCF1(+)CD8(+) T cells for ICB efficacy may differ across tumor contexts. We find that TCF1 is essential for optimal priming of tumor antigen-specific CD8(+) T cells and ICB response in poorly immunogenic tumors that accumulate TOX(+) dysfunctional T cells, but is dispensable for T cell priming and therapy response in highly immunogenic tumors that efficiently expand transitory effectors. Importantly, improving T cell priming by vaccination or by enhancing antigen presentation on tumors rescues the defective responses of TCF1-deficient CD8(+) T cells upon ICB in poorly immunogenic tumors. Our study highlights TCF1's role during the early stages of anti-tumor CD8(+) T cell responses with important implications for guiding optimal therapeutic interventions in cancers with low TCF1(+)CD8(+) T cells and low-neo-antigen expression. |
